Michael Yeh, MD
Advanced Heart Failure and Transplant Cardiology · Alhambra, CANPI 1265458954
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,569 of the $9,100 with a category attached, or 83.2%. It is spread thinly across 36 manufacturers, the largest accounting for just 23.6% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in CA, where the typical reported total is $9,367.
Across 420 payments — averaging $21.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$2K
- Novartis$1K
- Amgen$887
- Johnson & Johnson$577
- Boehringer Ingelheim$540
- Merck$504
- plus $3K from 30 others
Across 1 payment — averaging $286.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$287
What the payments were for
- Consulting fees$1,50016%
- Food & beverage$7,56983%
- Education$310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 24 | $2,152 |
| Novartis | 69 | $1,093 |
| Amgen | 48 | $887 |
| Johnson & Johnson | 45 | $577 |
| Boehringer Ingelheim | 26 | $540 |
| Merck | 19 | $504 |
| Pfizer | 28 | $466 |
| AstraZeneca | 25 | $465 |
| Actelion Pharmaceuticals US, Inc. | 20 | $371 |
| E.r. Squibb & Sons, L.L.C. | 23 | $299 |
| Sanofi-aventis U.S. LLC | 15 | $271 |
| Amarin Pharma, Inc. | 13 | $270 |
| Lundbeck LLC | 17 | $202 |
| Esperion Therapeutics, Inc. | 8 | $184 |
| Cvrx, Inc. | 2 | $104 |
| Abbott | 4 | $93 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $84 |
| Kestra Medical Technology Services, Inc. | 3 | $66 |
| Arbor Pharmaceuticals, Inc. | 4 | $66 |
| Alnylam Pharmaceuticals Inc. | 2 | $60 |
| Xeris Pharmaceuticals, Inc. | 2 | $36 |
| United Therapeutics Corporation | 2 | $36 |
| Edwards Lifesciences | 1 | $31 |
| Impulse Dynamics (USA) Inc. | 1 | $28 |
| Tactile Systems Technology Inc | 2 | $27 |
| Gilead | 1 | $22 |
| Boston Scientific | 1 | $19 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $19 |
| GSK | 1 | $19 |
| Lexicon Pharmaceuticals, Inc. | 1 | $18 |
| Angiodynamics, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Medtronic | 1 | $15 |
| Amryt Pharma Holdings Ltd | 1 | $15 |
| Irhythm Technologies, Inc. | 1 | $14 |
| Bardy Diagnostics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,100 in reported general payments places this provider in the 45th percentile of 111 advanced heart failure and transplant cardiology providers in California.
See all advanced heart failure and transplant cardiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 922 | $781,976 |
| EntrestoSacubitril/Valsartan | 609 | $589,656 |
| XareltoRivaroxaban | 183 | $187,535 |
| JardianceEmpagliflozin | 170 | $145,858 |
| Repatha SureclickEvolocumab | 148 | $109,751 |
| Repatha PushtronexEvolocumab | 64 | $47,241 |
| BrilintaTicagrelor | 71 | $46,344 |
| MultaqDronedarone Hcl | 35 | $45,169 |
| FarxigaDapagliflozin Propanediol | 53 | $38,250 |
| VascepaIcosapent Ethyl | 69 | $35,036 |
| Repatha SyringeEvolocumab | 30 | $24,599 |
| Praluent PenAlirocumab | 37 | $24,359 |
| CorlanorIvabradine Hcl | 33 | $20,270 |
| JanuviaSitagliptin Phosphate | 15 | $13,564 |
| EdarbiAzilsartan Medoxomil | 30 | $13,331 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $466 | $781,976922 claims |
| NovartisEntresto | $1,093 | $589,656609 claims |
| Johnson & JohnsonXarelto | $577 | $187,535183 claims |
| Boehringer IngelheimJardiance | $540 | $145,858170 claims |
| AstraZenecaBrilinta, Farxiga | $465 | $84,594124 claims |
| Sanofi-aventis U.S. LLCMultaq | $271 | $45,16935 claims |
| MerckJanuvia, Verquvo | $504 | $21,82826 claims |
| AmgenCorlanor | $887 | $20,27033 claims |
| Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor | $66 | $16,65842 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $17 | $4,55511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 111 advanced heart failure and transplant cardiology providers in California.
Other advanced heart failure and transplant cardiology in Alhambra
- Richard WrightSanta Monica$1.7M
- James Heywoodla Jolla$1.2M
- Hirsch MehtaSan Diego$494K
- Teresa de MarcoSan Francisco$366K
- Rajeev Mohanla Jolla$357K
- Marcus UreySan Diego$341K
- Munir JanmohamedSacramento$314K
- Barry GreenbergSan Diego$270K
- Ronald WittelesStanford$251K
- Gurpreet SodhiSacramento$241K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.